Among them, a randomized phase II study for the Wilms’ tumor gene 1 (WT1) vaccine showed promising results [69]; WT1, which is ranked as the top antigen among 75 tumor-associated antigens (TAAs) [70], is one of the most promising TAAs. The gene discussed is WT1; the disease is neoplasm.